Document:

EX-10.5(B)

 Exhibit 10.5(B) 

Juno Therapeutics, Inc. 

307 Westlake Avenue North, Suite 300 

Seattle, WA 98109 
 December 21, 2015

 Fred Hutchinson Cancer Research Center 
 Industry
Relations & Technology Transfer 
 1100 Fairview Avenue North, J5-110 

Seattle, WA 98109-1024 
 Attention: Vice President for Technology
Transfer 
  

	Re:	Side Letter Agreement 

 Ladies and Gentlemen: 

Reference is made to the letter agreement dated as of October 16, 2013 (the “Original Letter Agreement”), by and
between Fred Hutchinson Cancer Research Center (“FHCRC”) and Juno Therapeutics, Inc., f/k/a FC Therapeutics, Inc. (the “Company”) in connection with the Collaboration Agreement, entered into as of the
same date (the “Collaboration Agreement”). This amendment to the Letter Agreement (this “Amendment” and, together with the Original Letter Agreement, the “Agreement”) is to
confirm the following mutual agreements between the parties: 
 1. Definitions. The parties hereby agree that, for all purposes under
the Original Letter Agreement and this Amendment: 
 (a) The definition of “Multiple of Initial Equity” in Section 2(c) of
the Original Letter Agreement is hereby deleted and replaced in its entirety as follows: 
 ““Multiple of Initial
Equity” means (A) the Success Payment Value divided by (B) $4.00 (as adjusted for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event).”

 (b) The definition of “Success Payment Date” in Section 2(c) of the Original Letter Agreement is hereby deleted and
replaced in its entirety as follows: 
 ““Success Payment Date” means (i) December 19, 2015 (plus a
90-day grace period at the Company’s option if the Company is contemplating capital market transactions during the grace period such as a secondary offering) (the “IPO Success Payment Date”), (ii) with respect to
any Success Payment arising as a result of a Company Sale Valuation Date, the earlier of (a) the date on which any proceeds from the Company Sale are paid or distributed to any stockholder, and (b) the date that is ninety (90) days
after the Company Sale Valuation Date, and (iii) with respect to any other Success Payment, the date that is ninety (90) days after the Valuation Date pursuant to which such Success Payment obligation arises; provided,
however, that for each of clauses (i) through (iii), if the applicable Success Payment Date would otherwise fall on a date that is not a business day, the applicable Success Payment Date shall instead occur on the next following business
day.” 
 (c) The definition of “Valuation Date” in Section 2(c) of the Original Letter Agreement is hereby deleted and
replaced in its entirety as follows: 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ““Valuation Date” is any one of the following dates that occur
during the Success Payment Period: (i) December 19, 2014 (the “IPO Valuation Date”); (ii) the date on which the Company or a successor sells, leases, transfers or exclusively licenses all or substantially all
of its assets to another company (an “Asset Sale”); (iii) the date on which the Company merges or consolidates with or into another entity (other than a merger in which the pre-merger stockholders of the Company own a
majority of the shares of the surviving entity) (a “Merger” and with an Asset Sale, a “Company Sale”, and the Valuation Dates triggered thereby each a “Company Sale Valuation
Date”), (iv) the dates on which ARCH Venture Fund VII, L.P. (“ARCH”) or CL Alaska L.P., or either of such entity’s affiliated entities that hold such shares (“CL Alaska”)
transfers a majority of its shares of company capital stock held by such entity on such date to a third party; (v) the bi-annual anniversary of any event described in the preceding clauses (i), (ii), (iii) or (iv), but only if FHCRC
requests, within twenty (20) calendar days after written notice of such event from the Company, that such date be considered a Valuation Date; and (vi) the last day of the Success Payment Period.” 

(d) The following terms shall have the following meanings for all purposes under the Agreement: 

“business day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed. 
 “common stock of the Company” or the
“Company’s common stock” or similar phrases means the common stock, par value $0.0001 per share, of the Company (or any other security of the Company or any successor entity into which the Series A Preferred Stock of the
Company have ultimately been converted). 
 “Closing Price” means the last closing trade price for the common stock
of the Company on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, as the case may be, then the last trade price of such security
prior to 4:00:00 p.m., New York time, as reported by Bloomberg. 
 “Principal Market” means the principal securities
exchange or securities market on which the common stock of the Company is listed or traded as reported by Bloomberg (which exchange, as of the date hereof, is The NASDAQ Global Select Market). 

“trading day” means any day on which the common stock of the Company is traded on the Principal Market;
provided, however, that “trading day” shall not include any day on which the common stock of the Company is scheduled to trade on the Principal Market for less than 4.5 hours or any day that the common stock of
the Company is suspended from trading during the final hour of trading on the Principal Market (or if the Principal Market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00
p.m., New York time). 
 2. Calculation of Fair Market Value. The parties hereby agree that: 

(a) With respect to the IPO Success Payment Date (as defined in this Amendment), the “average trading price of a share of common stock of
the Company over the consecutive 90-day period preceding” such IPO Success Payment Date, referred to in Paragraph 1 of Exhibit D of the Original Letter Agreement, shall be equal to the average of the Closing Prices of a share of the common
stock of the Company for each trading day during the 90 calendar day period preceding December 19, 2015, as listed on the Principal Market. 

(b) With respect to any Valuation Date that occurs on each bi-annual anniversary of the IPO Valuation Date pursuant to clause (v) of the
definition of “Valuation Date” as amended hereby (each such 

  
 2 

 
Valuation Date a “Subsequent IPO-Related Valuation Date”), the Fair Market Value of each share of the Series A Preferred Stock of the Company, for all purposes under the
Agreement, shall be determined as follows: (i) if the common stock of the Company is publicly tradable on one or more trading days during the 90 calendar days preceding such Subsequent IPO-Related Valuation Date, such Fair Market Value shall be
equal to the average of the Closing Prices of a share of the common stock of the Company for each day that the common stock was publically traded during such 90 calendar day period and (ii) if the common stock of the Company is not publicly
tradable for at least one trading day during such 90 calendar day period, such Fair Market Value shall be determined pursuant to paragraph 4 of Exhibit D to the Original Letter Agreement. 

(c) The parties hereby agree and acknowledge that as of the date hereof, no dividends or other distributions referenced in clause (i) of
the definition of “Success Payment Value” have been made. 
 3. Calculation of Success Payments. If, pursuant to and as
permitted by Section 2(a) of the Original Letter Agreement, the Company elects in its sole discretion to satisfy an obligation to make a Success Payment on a Success Payment Date, including on the IPO Success Payment Date or any Success Payment
Date arising from a Subsequent IPO-Related Valuation Date (a “Subsequent IPO-Related Success Payment Date”), through the issuance to FHCRC of shares of common stock of the Company, the number of such shares issuable to FHCRC
in satisfaction of such Success Payment shall be equal to (i) (A) the dollar amount of such Success Payment less (B) any indirect cost offsets attributable to FHCRC pursuant to the side letter, dated June 11, 2014, between
FHCRC and the Company as amended by the letter dated December 21, 2015, both of which are attached hereto as Exhibit A (the “Indirect Costs Letters”) with respect to Sponsor Payments (as such term is defined in
the Collaboration Agreement) that have been paid to FHCRC, or billed by but not yet paid to FHCRC, as of the Success Payment Date (“Indirect Costs”), divided by (ii) the volume weighted average trading price of a
share of the common stock of the Company on the Principal Market for the last trading day preceding the applicable Success Payment Date as reported by Bloomberg. To the extent that the amount deducted by the Company as Indirect Costs pursuant to
clause (i)(B) above is disputed, the parties shall cooperate in good faith to resolve such dispute; provided, however, that the Company shall in any event be entitled to deduct any amount it believes in good faith to constitute
Indirect Costs from the applicable Success Payment; provided, further, that to the extent that it is determined following the Success Payment Date that the amount deducted as Indirect Costs pursuant to clause (i)(B) from the applicable
Success Payment was in excess of actual Indirect Costs as of the Success Payment Date, the amount of such excess shall be paid by the Company to FHCRC in cash (even if the Company had elected to make the associated Success Payment in stock). 

4. Miscellaneous. The Agreement will be construed, interpreted, and applied in accordance with the laws of the State of Delaware,
excluding its body of law controlling conflicts of laws. This Amendment shall apply and be effective only with respect to the provisions of the Original Letter Agreement specifically referred to herein. Except to the extent expressly modified by
this Amendment, the Original Letter Agreement remains in full force and effect. To the extent of any inconsistency between this Amendment and the Original Letter Agreement, the terms and conditions of this Amendment shall control. The rights and
obligations under this letter agreement may not be assigned, and any attempt to do so will be null and void, without the prior written consent of the Company; provided, however, that FHCRC may assign its rights under this letter
agreement to any direct or indirect wholly owned subsidiary of FHCRC that acquires shares of the capital stock of the Company from FHCRC so long as such wholly owned subsidiary of FHCRC agrees to be bound by the terms and provisions of this letter
agreement. This Amendment may not be amended except by the written agreement signed by authorized representatives of both parties and may be executed in counterparts, with signatures delivered by facsimile or .pdf binding as if originally executed.

 [Signature Page Follows] 

  
 3 

 This letter agreement is the complete and exclusive statement regarding the subject matter of
this agreement and supersedes all prior agreements, understandings and communications, oral or written, between the parties regarding the subject matter of this letter agreement. 

 

			
	With best regards,
	
	JUNO THERAPEUTICS, INC.
		
	By:	 	 /s/ Steven Harr

	Name:	 	Steven Harr
	Title:	 	CFO

 Accepted and Agreed: 
  

			
	FRED HUTCHINSON CANCER RESEARCH CENTER
		
	By:	 	 /s/ Nicole C. Robinson            

	Name:	 	Nicole C. Robinson, Ph.D.
	Title:	 	VP, Business Development & Industry Relations

 Fred Hutchinson Cancer Research Center 

Industry Relations & Technology Transfer 
 1100 Fairview
Avenue North, J5-110 
 Seattle, WA 98109-1024 
 Attention: Vice
President for Technology Transfer 

  
 4 

 EXHIBIT A 

Indirect Costs Letter 

 [Juno Letterhead] 

June 11, 2014 
 Mr. Doug Shaeffer 

Vice President & General Counsel 
 Fred Hutchinson Cancer
Research Center 
 1100 Fairview Ave., North 
 Seattle, WA 98109

  

	Re:	Collaboration Agreement entered October 16, 2013 and Side Letter Agreement dated October 15, 2013 

Dear Mr. Shaeffer: 
 This letter agreement
relates to (a) that certain Collaboration Agreement entered into by and between Fred Hutchinson Cancer Research Center (“FHCRC”) and FC Therapeutics, Inc. (now Juno Therapeutics, Inc.) (“Juno”) as of
October 16, 2013 (the “Agreement”) and (b) that certain Side Letter entered into by and between FHCRC and Juno dated October 15, 2013 relating to Success Payments (the “Side Letter”). The defined
terms used in this letter shall have the respective meanings set forth in the Agreement and the Side Letter. 
 FHCRC and Juno hereby agree
that any portion of any [***] by Juno for [***] conducted by FHCRC that are attributed to indirect costs [***] as reflected in [***] shall be [***] creditable against any Success Payments due to FHCRC pursuant to Section 2 of the Side Letter.
The foregoing credit provisions of this paragraph apply only to [***] and do not apply to (1) the [***] or (2) services provided by FHCRC under [***]. 

FHCRC and Juno further agree that (i) for [***], FHCRC will charge Juno [***], and (ii) for all other Collaboration Projects, FHCRC
will charge Juno [***]. 
 Except as expressly provided in this letter, all terms of the Agreement and Side Letter shall remain in effect
without modification. 
 Please indicate the agreement of FHCRC to the foregoing by countersigning below. 

Yours Sincerely, 

/s/ Hans Bishop 

Hans Bishop 
  

			
	UNDERSTOOD AND AGREED BY FHCRC:
		
	By:	 	 /s/ Randall C. Main

		
	Name:	 	 Randall C. Main

		
	Title:	 	 VP & CFO

		
	Date:	 	 June 12, 2014

  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 [Fred Hutch Letterhead] 

December 21, 2015 
 Hans Bishop 

Chief Executive Officer & President 
 Juno Therapeutics,
Inc. 
 307 Westlake Ave. N., St. 300 
 Seattle, Washington
98109 
  

	 	Re:	Amendment to F&A Side Letter dated June 11, 2014 

 Dear Hans: 

The purpose of this letter is to clarify and amend certain terms of the letter from Hans Bishop to Doug Shaeffer dated June 11, 2014 and agreed to on
behalf of the Fred Hutchinson Cancer Research Center (“FHCRC”) by Randall C. Main on June 12, 2014 (“F&A Side Letter”), concerning the offset of certain indirect costs against FHCRC’s Success Payments
(as defined in the certain Side Letter Agreement between the parties dated October 16, 2013, as amended from time to time). Unless otherwise defined in this letter, capitalized terms used in this letter will have the meanings assigned to them
in the F&A Side Letter. 
 FHCRC and Juno Therapeutics, Inc. (“Juno”) hereby agree as follows: 

 

	 	1.	All credits against Success Payments described in the F&A Side Letter will be [***] to the extent based on the indirect costs charged with respect to [***]. In addition, FHCRC and Juno agree that, with respect to
any such [***], FHCRC shall continue to charge (and Juno shall be obligated to continue to pay) [***]. FHCRC represents and warrants that, as of the date of this letter, the [***]. If at any time, FHCRC [***], FHCRC shall promptly notify Juno in
writing of [***]. 

  

	 	2.	FHCRC and Juno agree that, from and after the date of this letter, the phrase “For a period of [***] commencing on the Effective Date” in Section 5.4(a) of the Collaboration Agreement is hereby deleted
and replaced with the phrase “For a period of [***] commencing on the Effective Date”. 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	Amendment to F&A Side Letter	  	December 21, 2015

 Page 2 
  

	 	3.	Except as expressly provided in this letter, all terms of the F&A Side Letter will remain in effect without modification. 

Please indicate the agreement of Juno Therapeutics, Inc. to the foregoing by countersigning below. 

Yours Sincerely, 
  

			
	 /s/ D. Gary Gilliland
	 	
		
	 D. Gary Gilliland, M.D., Ph.D.
	 	

  

			
	 Terms agreed to December 21, 2015.

 
 Juno Therapeutics, Inc.

 
	  	

  

			
	By:	 	 /s/ Jim J. MacDonald

		
	Its:	 	 Chief Intellectual Property Officer

  
 2EX-10.10(B)

 Execution Copy 

Exhibit 10.10(B) 
 Juno
Therapeutics, Inc. 
 307 Westlake Avenue North, Suite 300 

Seattle, WA 98109 
 December 14, 2015

 Memorial Sloan-Kettering Cancer Center 
 1275 York Avenue

 New York, NY10065 
  

	Re:	Side Letter Agreement 

 Ladies and Gentlemen: 

Reference is made to the letter agreement dated as of November 21, 2013 (the “Original Letter Agreement”), by and
between Memorial Sloan-Kettering Cancer Center (“MSKCC”) and Juno Therapeutics, Inc., f/k/a FC Therapeutics, Inc. (the “Company”) in connection with the Master Clinical Studies Agreement, the Master
Sponsored Research Agreement and the Exclusive License Agreement, entered into as of the same date (the “Collaboration Agreements”). This amendment to the Letter Agreement (this “Amendment” and,
together with the Original Letter Agreement, the “Agreement”) is to confirm the following mutual agreements between the parties: 

1. Definitions. The parties hereby agree that, for all purposes under the Original Letter Agreement and this Amendment: 

(a) The definition of “Multiple of Initial Equity” in Section 1 of the Original Letter Agreement is hereby deleted and replaced
in its entirety as follows: 
 ““Multiple of Initial Equity” means (A) the Success Payment
Value divided by (B) $4.00 (as adjusted for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event).” 

(b) The definition of “Success Payment Date” in Section 1 of the Original Letter Agreement is hereby deleted and replaced in
its entirety as follows: 
 ““Success Payment Date” means (i) March 18, 2016 (the “IPO
Success Payment Date”), (ii) with respect to any Success Payment arising as a result of a Company Sale Valuation Date, the earlier of (a) the date on which any proceeds from the Company Sale are paid or distributed to any
stockholder, and (b) the date that is ninety (90) days after the Company Sale Valuation Date, and (iii) with respect to any other Success Payment, the date that is ninety (90) days after the Valuation Date pursuant to which such
Success Payment obligation arises; provided, however, that for each of clauses (i) through (iii), if the applicable Success Payment Date would otherwise fall on a date that is not a business day, the applicable Success Payment
Date shall instead occur on the next following business day.” 
 (c) The definition of “Valuation Date” in Section 1 of
the Original Letter Agreement is hereby deleted and replaced in its entirety as follows: 
 ““Valuation Date”
is any one of the following dates that occur during the Success Payment Period: (i) December 19, 2014 (the “IPO Valuation Date”); (ii) the date on which the Company or a successor 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 sells, leases, transfers or exclusively licenses all or substantially all of its assets to another company (an
“Asset Sale”); (iii) the date on which the Company merges or consolidates with or into another entity (other than a merger in which the pre-merger stockholders of the Company own a majority of the shares of the surviving
entity) (a “Merger” and with an Asset Sale, a “Company Sale”, and the Valuation Dates triggered thereby each a “Company Sale Valuation Date”), (iv) the dates on which ARCH
Venture Fund VII, L.P. (“ARCH”) or CL Alaska L.P., or either of such entity’s affiliated entities that hold such shares (“CL Alaska”) transfers a majority of its shares of company capital stock
held by such entity on such date to a third party; (v) every second anniversary of any event described in the preceding clauses (i), (ii), (iii) or (iv); and (vi) the last day of the Success Payment Period. For the avoidance of doubt,
and by way of further explanation of clause (v) above, a Valuation Date under clause (v), with respect to the IPO Valuation Date, occurs on December 19, 2016, December 19, 2018 and every even-numbered year thereafter.” 

(d) The following terms shall have the following meanings for all purposes under the Agreement: 

“business day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed. 
 “common stock of the Company” or the
“Company’s common stock” or similar phrases means the common stock, par value $0.0001 per share, of the Company (or any other security of the Company or any successor entity into which the Series A Preferred Stock of the
Company has ultimately been converted). 
 “Closing Price” means the last closing trade price for the common stock
of the Company on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, as the case may be, then the last trade price of such security
prior to 4:00:00 p.m., New York time, as reported by Bloomberg. 
 “Principal Market” means the principal securities
exchange or securities market on which the common stock of the Company is listed or traded as reported by Bloomberg (which exchange, as of the date hereof, is The NASDAQ Global Select Market). 

“trading day” means any day on which the common stock of the Company is traded on the Principal Market;
provided, however, that “trading day” shall not include any day on which the common stock of the Company is scheduled to trade on the Principal Market for less than 4.5 hours or any day that the common stock of
the Company is suspended from trading during the final hour of trading on the Principal Market (or if the Principal Market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00
p.m., New York time). 
 2. Calculation of Fair Market Value. The parties hereby agree that: 

(a) With respect to the IPO Success Payment Date (as defined in this Amendment), the “average trading price of a share of common stock of
the Company over the consecutive 90-day period preceding” such IPO Success Payment Date, referred to in Paragraph 1 of Exhibit A of the Original Letter Agreement, shall be equal to the average of the Closing Prices of a share of the common
stock of the Company for each trading day during the 90 calendar day period preceding December 19, 2015, as listed on the Principal Market. Therefore, by way of example, if the average Closing Price of a share of the common stock of the Company
over the 90-calendar day period preceding December 19, 2015, as calculated in accordance herewith, exceeds $40 per share, a Success Payment of $10 million (less Indirect Costs, as calculated herein) will be due and payable no later than the IPO
Success Payment Date (March 18, 2016), as described in the definition of “Success Payment Date.” 

  
 2 

 (b) With respect to each Valuation Date that occurs on each second anniversary of the IPO
Valuation Date pursuant to clause (v) of the definition of “Valuation Date” as amended hereby (each such Valuation Date a “Subsequent IPO-Related Valuation Date”), the Fair Market
Value shall be determined as follows: (i) if the common stock of the Company is publicly tradable during the 90 calendar days preceding such Subsequent IPO-Related Valuation Date, such Fair Market Value shall be equal to the average of the
Closing Prices of a share of the common stock of the Company for each trading day during such 90 calendar day period and (ii) if the common stock of the Company is not publicly tradable during such 90 calendar day period, such Fair Market Value
shall be determined pursuant to paragraph 4 of Exhibit A to the Original Letter Agreement.  
 (c) The parties hereby agree and
acknowledge that as of the date hereof, no dividends or other distributions referenced in clause (i) of the definition of “Success Payment Value” have been made. 

3. Calculation of Success Payments. If, pursuant to and as permitted by Section 3(a) of the Original Letter Agreement, the Company
elects in its sole discretion to satisfy an obligation to make a Success Payment on a Success Payment Date, including on the IPO Success Payment Date or any Success Payment Date arising from a Subsequent IPO-Related Valuation Date (a
“Subsequent IPO-Related Success Payment Date”), through the issuance to MSKCC of shares of common stock of the Company, the number of such shares issuable to MSKCC in satisfaction of such Success Payment shall be equal to
(i) (A) the dollar amount of such Success Payment less (B) any indirect cost offsets (“Indirect Costs”) attributable to MSKCC pursuant to the side letter, dated October 2, 2015, between for MSKCC
and the Company, attached hereto as Exhibit A (the “Indirect Costs Letter”), divided by (ii) the volume weighted average trading price of a share of the common stock of the Company on the Principal Market
for the last trading day preceding the applicable Success Payment Date as reported by Bloomberg. To the extent that the amount deducted by the Company as Indirect Costs pursuant to clause (i)(B) above is disputed, the parties shall cooperate in good
faith to resolve such dispute; provided, however, that the Company shall in any event be entitled to deduct any amount it believes in good faith to constitute Indirect Costs from the applicable Success Payment; provided,
further, that to the extent that it is determined following the Success Payment Date that the amount deducted as Indirect Costs pursuant to clause (i)(B) from the applicable Success Payment was in excess of actual Indirect Costs as of the
Success Payment Date, the amount of such excess shall be paid by the Company to MSKCC in cash (even if the Company had elected to make the associated Success Payment in stock). By way of example, if a Success Payment of $10 million becomes required
as of the IPO Success Payment Date, the number of shares to be issued to MSKCC (if Juno elects to satisfy its payment obligation by issuance of common stock by the Company) would be determined by dividing $10 million (less any deduction for Indirect
Costs pursuant to clause (i)(B) above) by the volume weighted average trading price of a share of such common stock on the Principal Market for the last trading day preceding the IPO Success Payment Date (which, based on an IPO Success Payment Date
of March 18, 2016, is expected to be March 17, 2016) as reported by Bloomberg. The parties agree that, solely for purpose of calculating the number of shares deliverable by the Company on the IPO Success Payment Date, the Indirect Costs
will not be deemed to exceed $1.1 million. Any refund required to be made by Juno to MSKCC under the Indirect Costs Letter for an [***] Offset Amount (as defined in the Indirect Costs Letter) shall be paid in cash even if Juno had elected to make
the associated Success Payment in stock. 
 4. Miscellaneous. This Amendment shall apply and be effective only with respect to the
provisions of the Original Letter Agreement specifically referred to herein. Except to the extent expressly modified by this Amendment, the Original Letter Agreement remains in full force and effect. To the extent of any inconsistency between this
Amendment and the Original Letter Agreement, the terms and conditions of this Amendment shall control. 
 [Signature Page Follows] 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 
			
	
	With best regards,
	
	JUNO THERAPEUTICS, INC.
		
	By:	 	 /s/ Hans Bishop

	Name:	 	
	Title:	 	

 Accepted and Agreed: 
  

	
	MEMORIAL SLOAN-KETTERING CANCER CENTER
	
	 /s/ Gregory Raskin            

	Gregory Raskin, MD – Executive Director,
	Office of Technology Development

 Memorial Sloan-Kettering Cancer Center 

Office of Technology Development 
 1275 York Avenue 

New York, NY 10065 
 Attn: Gregory Raskin, MD – Executive
Director 
 Ph.: [omitted] 
 Fax: [omitted] 

Email: [omitted] 

 EXHIBIT A 

Indirect Costs Letter 

 October 1, 2015 

Dr. Greg Raskin 
 Memorial Sloan Kettering Cancer Center

 1275 York Avenue 
 New York, NY 10065 

 

	Re:	Indirect Costs and Advance Payments 

 Dear Dr. Raskin: 

This letter agreement relates to (a) that certain Master Sponsored Research Agreement between Memorial Sloan Kettering Cancer Center
(“MSKCC”) and Juno Therapeutics, Inc. (“Juno”) dated November 21, 2013 (“MSRA”), (b) that certain Master Clinical Trial Agreement between MSKCC and Juno dated November 21, 2013
(“MCTA”), (c) that certain Side Letter Agreement between MSKCC and Juno dated November 21, 2013 (“Side Letter”), (d) that certain Clinical Trial Agreement between MSKCC and Juno dated July 8,
2014 and having contract identifier SK# 2014-0915 (“ALL Trial Agreement”), and (e) that certain Clinical Trial Agreement between MSKCC and Juno dated December 12, 2014 and having contract identifier SK# 2014-1885
(“MUC16 Trial Agreement”). The MSRA (including any agreements entered into thereunder), MCTA (including any agreements entered into thereunder), Side Letter, ALL Trial Agreement, MUC16 Trial Agreement, and any other agreement
entered into during the [***], are hereinafter collectively referred to as “Subject Agreements.” 
 MSKCC and Juno agree
that, except with respect to [***] which shall not be modified by this letter agreement: (i) for all clinical trial conducted under the Subject Agreements, MSKCC shall charge Juno [***]; (ii) for all research services conducted pursuant to
the Subject Agreements, MSKCC shall charge Juno [***]; and (iii) notwithstanding the foregoing, for all process development services, study product manufacturing, and related services under the Subject Agreements but not described above in
subsections (i) and (ii), MSKCC shall charge Juno [***]. 
 MSKCC and Juno agree that the Gene Transfer and Somatic Cell Engineering
Facility (“GTF”) per patient costs (including, without limitation, any study product production and post infusion follow-up) under or for: (A) the [***]; and (B) any clinical trials other than those identified in
subsection (A) above shall be [***]. 
 MSKCC and Juno agree that: (I) the [***] indirect costs [***] under [***] shall be [***]
creditable against the first Success Payment (as defined in the Side Letter) due to MSKCC under the Side Letter; and (II) [***] indirect costs [***] for [***] shall be first [***] creditable against the second Success Payment due to MSKCC under the
Side Letter and then against any subsequent Success Payment. For clarity, (x) the amount of such indirect costs actually paid by Juno to MSKCC before the corresponding Success Payment(s) is/are made may be deducted from that Success Payment,
and (y) such amounts that [***] may also be deducted from that Success Payment, subject to the true-up provided in the following paragraph. 

To the extent that any of the clinical studies and/or trials identified in subsections (I) or (II) above do not [***], Juno shall refund
the [***] indirect costs allocated to any such [***] (the “[***] Offset Amount”) within [***] after Juno’s receipt of an invoice from MSKCC for such [***] Offset Amount. For clarification, Juno’s rights to take the credits
set forth in this paragraph are contingent upon the ultimate payment of one or more Success Payments. In no event shall the credits allowed Juno by this paragraph be applied in a way that requires an out-of-pocket cash payment from MSKCC to Juno.

  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 MSKCC and Juno agree that, except with respect to Project Statement of Work #1 under the MSRA
which shall not be modified by this letter agreement, the [***] indirect costs [***] for [***] shall be first [***] creditable against the second Success Payment due to MSKCC under the Side Letter and then against any subsequent Success Payment.

 Except as expressly provided in this letter, all terms of the MSRA, MCTA, Side Letter, ALL Trial Agreement and MUC16 Trial Agreement
shall remain in effect without modification. 
 Please indicate the agreement of MSKCC to the foregoing by countersigning below. 

 

	
	Yours Sincerely,
	
	/s/ Hans Bishop
	
	Hans Bishop

  

			
	UNDERSTOOD AND AGREED BY MSKCC:
		
	By:	 	 /s/ Gregory Raskin

		
	Name:	 	 Gregory Raskin, M.D.

		
	Title:	 	 Vice President, Technology Development

		
	Date:	 	 10/2/15

  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]